Skip to main content
Premium Trial:

Request an Annual Quote

Lifebit Biotech Closes $60M Series B Funding Round

NEW YORK – Lifebit Biotech said this week that it has closed a Series B funding round worth $60 million.

Tiger Global Management led the round, with participation from previous investors Eurazeo, Pentech Ventures, and Beacon Capital. 

London-based Lifebit is a biomedical software firm that makes CloudOS, a cloud-native, federated genomics operating system for precision medicine. CloudOS functions as a managed service of individual clouds or high-performance computing centers to support analysis of bioinformatics data across sites and institutions.

In a statement, Lifebit CEO Maria Chatzou Dunford said that the company would use the new funding to expand its global presence and expand its workforce.

"We are confident that Lifebit's innovative … software solutions, paired with their customer-first approach, will drive rapid global adoption and accelerate breakthroughs in precision medicine," added John Curtius, partner at Tiger Global.

Lifebit closed a £6 million ($8.1 million) Series A funding round in April 2020.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.